Detalhe da pesquisa
1.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259589
2.
The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
Transfus Apher Sci
; 62(6): 103787, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37704508
3.
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Br J Haematol
; 188(6): 918-923, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682002
4.
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Blood
; 132(23): 2446-2455, 2018 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30287523
5.
Current landscape for chimeric antigen receptor T cells in lymphomas.
Curr Opin Hematol
; 26(6): 421-426, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31483334
6.
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Blood
; 128(18): 2199-2205, 2016 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27601462
7.
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Haematologica
; 103(9): 1511-1517, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880613
8.
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Am J Hematol
; 93(11): 1394-1401, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30132965
9.
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Blood
; 135(21): 1912-1915, 2020 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32302379
10.
A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Biol Blood Marrow Transplant
; 22(12): 2165-2171, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27590107
11.
Mantle cell lymphoma: state of the art.
Clin Adv Hematol Oncol
; 13(1): 44-55, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25679973
12.
An indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive CLL.
Blood Adv
; 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598745
13.
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
J Clin Oncol
; 41(10): 1876-1887, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608310
14.
Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation.
Transplant Cell Ther
; 27(5): 391-403, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33965177
15.
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cancer Med
; 9(22): 8468-8479, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32969597
16.
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Clin Cancer Res
; 26(14): 3589-3596, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32198151
17.
A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma.
Bone Marrow Transplant
; 54(11): 1881-1891, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101891
18.
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
Clin Cancer Res
; 25(14): 4264-4270, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31004001
19.
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.
Blood Adv
; 3(10): 1568-1573, 2019 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101647
20.
The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.
Ther Adv Hematol
; 8(3): 99-105, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28246553